<div id="readability-page-1"><div><p>Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2025. These A Shares will be under lockup for 1837 days starting from 10-SEP-2020 to 21-SEP-2025.</p><p>  Details:<br/> The company shareholders, namely, Ningbo Zhongjin Guolian Xinde Equity Investment Partnership (Limited Partnership), Wuxi Hongshi Huiquan Equity Investment Management Center (Limited Partnership), Qiu Weihong, issuer directors, Chu Yizhou and Liu Meihua, issuer's director and general manager Chu Dingjun have agreed not to dispose of their interest for a period of 12 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect.</p><p>  The company controlling shareholders, namely, Zhejiang Tongben Investment Co., Ltd., Tiantai Platinum Investment Partnership (Limited Partnership), chairman and actual controller, namely, Peng Zhien, Director Qiu Peijing, Li Jianwen, Chairman of the Board of Supervisors Jin Ping, senior manager of the issuer, Xin Mingyan, Chen Jieming, Zhang Liqin, Wang Xiuyu, Li Fangfang, employee supervisor Yang Liwei have agreed not to dispose of their interest for a period of 36 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect.</p><p>The controlling shareholder, namely, Tiantai Platinum Investment Management Partnership (Limited Partnership), and deputy general manager of the issuer, Wang Guoping have agreed not to dispose of their interest for a period of 60 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect.</p></div></div>

奧鋭特

<p>奧鋭特製藥有限公司的部分 A 股在鎖定協議下，直到 2025 年 9 月 21 日，鎖定期為 1837 天，自 2020 年 9 月 10 日起計算。包括寧波中金國聯和無錫鴻石匯泉在內的股東在上市後 12 個月內不得處置其股份，具體情況可能根據股價表現進行延長。控股股東面臨 36 個月的鎖定期，而另一組股東則有 60 個月的限制。鎖定期結束後，年度股份轉讓限制為持股的 25%</p>

奧鋭特製藥股份有限公司的部分 A 股受到鎖定協議的限制，該協議將於2025年9月21日到期